Physician profile
David Thrasher
NPI 1831150259
$1,961.07
in general payments reported to CMS, 2019-2025
15 companies · $26.73 in 2025
The $26.73 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $584 · 2020: $419 · 2021: $433 · 2022: $462 · 2023: $35.89 · 2025: $26.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $62.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $62.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $976.13 | 2019-2023 | Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $207.78 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $170.01 | 2019-2021 | |
| Gilead Sciences, INC. | $101.40 | 2021-2022 | |
| Grifols USA, LLC | $91.12 | 2021-2022 | |
| Genentech USA, INC. | $80.20 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $70.77 | 2019-2021 | |
| Philips North America LLC | $58.73 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $54.02 | 2020-2022 | |
| Paratek Pharmaceuticals, INC. | $37.14 | 2021 | |
| Electromed, INC. | $31.13 | 2019 | |
| Amgen INC. | $26.73 | 2025 | Krystexxa |
| Regeneron Healthcare Solutions, INC. | $23.88 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $16.76 | 2019 | |
| Inogen, INC. | $15.27 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Thrasher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.